Tuberous sclerosis laboratory findings: Difference between revisions
(Created page with "__NOTOC__ {{Tuberous sclerosis}} {{CMG}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==Ove...") |
Jose Loyola (talk | contribs) No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Tuberous sclerosis}} | {{Tuberous sclerosis}} | ||
{{CMG}} | {{CMG}} {{AE}} {{Jose}} | ||
==Overview== | |||
[[Molecular genetic testing]] is commercially available for tuberous sclerosis. | |||
== | == Laboratory Findings == | ||
[[Molecular genetic testing]] is commercially available in the United States for the diagnosis of [[tuberous sclerosis]]. Genetic testing identifies mutations only in 75% - 80%. The 15%-20% failure rate is thought to be due to somatic mosaicism. Therefore a negative genetic test does not rule out the diagnosis of tuberous sclerosis. | [[Molecular genetic testing]] is commercially available in the United States for the diagnosis of [[tuberous sclerosis]]. [[Genetic testing]] identifies [[mutations]] only in 75% - 80%. The 15%-20% failure rate is thought to be due to [[somatic]] [[mosaicism]]. Therefore a negative genetic test does not rule out the diagnosis of tuberous sclerosis. If a case meets the clinical [[diagnostic criteria]], then it is performed a genetic molecular testing which is seem mostly as corroborative.<ref name="PMID17005952">{{cite journal | vauthors = Crino PB, Nathanson KL, Henske EP | title = The tuberous sclerosis complex | journal = The New England Journal of Medicine | volume = 355 | issue = 13 | pages = 1345–56 | date = September 2006 | pmid = 17005952 | doi = 10.1056/NEJMra055323 }}</ref> | ||
There are no typical diagnostic laboratory findings associated with tuberous sclerosis. Patients may present with elevated [[BUN]] or [[creatinine]] if their renal [[Angiomyolipoma|angiomyolipomas]] compromise renal function or if they also present with [[Autosomal dominant polycystic kidney disease|autosomal dominant polycystic kidney]] disease. | |||
==References== | ==References== | ||
Latest revision as of 17:56, 23 June 2020
|
Tuberous sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tuberous sclerosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Tuberous sclerosis laboratory findings |
|
Risk calculators and risk factors for Tuberous sclerosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: José Eduardo Riceto Loyola Junior, M.D.[2]
Overview
Molecular genetic testing is commercially available for tuberous sclerosis.
Laboratory Findings
Molecular genetic testing is commercially available in the United States for the diagnosis of tuberous sclerosis. Genetic testing identifies mutations only in 75% - 80%. The 15%-20% failure rate is thought to be due to somatic mosaicism. Therefore a negative genetic test does not rule out the diagnosis of tuberous sclerosis. If a case meets the clinical diagnostic criteria, then it is performed a genetic molecular testing which is seem mostly as corroborative.[1]
There are no typical diagnostic laboratory findings associated with tuberous sclerosis. Patients may present with elevated BUN or creatinine if their renal angiomyolipomas compromise renal function or if they also present with autosomal dominant polycystic kidney disease.
References
- ↑ Crino PB, Nathanson KL, Henske EP (September 2006). "The tuberous sclerosis complex". The New England Journal of Medicine. 355 (13): 1345–56. doi:10.1056/NEJMra055323. PMID 17005952.